Download PDF
Semin Respir Crit Care Med 2020; 41(01): 099-114
DOI: 10.1055/s-0039-3401992
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Mucormycosis

Gail Reid
1   Division of Infectious Diseases, Department of Medicine, Loyola University Medical Center and Stritch School of Medicine, Maywood, Illinois
,
Joseph P. Lynch III
2   Division of Pulmonary, Critical Care Medicine, Allergy, and Clinical Immunology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
,
Michael C. Fishbein
3   Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
,
Nina M. Clark
1   Division of Infectious Diseases, Department of Medicine, Loyola University Medical Center and Stritch School of Medicine, Maywood, Illinois
› Author Affiliations
Further Information

Publication History

Publication Date:
30 January 2020 (online)

    Permissions and Reprints

Abstract

Mucormycosis is an infection caused by a group of filamentous molds within the order Mucorales. Infections may result from ingestion of contaminated food, inhalation of spores into the nares or lungs, or inoculation into disrupted skin or wounds. In developed countries, mucormycosis occurs primarily in severely immunocompromised hosts (e.g., those with hematological malignancies, organ transplantation, neutropenia, autoimmune disorders, or other impairments in immunity). Only 6 to 10% of cases occur in subjects with no underlying disease. In contrast, in developing countries, most cases of mucormycosis occur in persons with poorly controlled diabetes mellitus or in immunocompetent subjects following trauma. Mucormycosis exhibits a marked propensity to invade blood vessels, leading to thrombosis, necrosis, and infarction of tissue. Mortality associated with invasive mucormycosis is high (> 30–50%), with 90% mortality associated with disseminated disease. Mortality rates are much lower, though still significant (10–30%), among patients with localized cutaneous disease.

The diagnosis of mucormycosis relies upon histopathology and culture. Blood tests are of limited diagnostic value. Even with disseminated disease, blood cultures are usually negative. Mucorales have a distinct histological appearance, with irregular, nonseptate hyphae that branch at right angles. Cultures and/or polymerase chain reaction (PCR) are important to identify the genera.

Based on anatomic localization, mucormycosis can be classified as one of six forms: (1) rhino-orbital-cerebral mucormycosis (ROCM), (2) pulmonary, (3) cutaneous, (4) gastrointestinal (GI), (5) disseminated, and (6) mucormycosis of uncommon sites. Among diabetics, ROCM is the most common clinical presentation, whereas lung involvement is uncommon. In contrast, among organ transplant recipients or patients with hematological malignancies (HemeM), pulmonary and disseminated diseases are most common. Mucormycosis can progress rapidly, and delay in initiation of treatment by even a few days markedly worsens outcomes.

Due to the rarity of mucormycosis, randomized controlled therapeutic trials have not been performed. Lipid formulations of amphotericin B (LFAB) are the mainstay of therapy, but the newer triazoles, posaconazole (POSA) and isavuconazole (ISAV) (the active component of the prodrug isavuconazonium sulfate), may be effective in patients refractory to or intolerant of LFAB. Early surgical debridement or excision plays an important adjunctive role. Additional studies are required to assess the optimal duration of therapy as well as the specific roles of LFAB and the triazoles in the treatment of mucormycosis.

Keywords

invasive fungal infections - mold - mucormycosis - Mucorales - Rhizopus - isavuconazole - posaconazole
 

  • References

  • 1 Chakrabarti A, Das A, Mandal J. , et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol 2006; 44 (04) 335-342
    CrossrefPubMedGoogle Scholar
  • 2 Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 2004; 10 (Suppl. 01) 31-47
    CrossrefPubMedGoogle Scholar
  • 3 Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012; 54 (Suppl. 01) S23-S34
    CrossrefPubMedGoogle Scholar
  • 4 Riley TT, Muzny CA, Swiatlo E, Legendre DP. Breaking the mold: a review of mucormycosis and current pharmacological treatment options. Ann Pharmacother 2016; 50 (09) 747-757
    CrossrefPubMedGoogle Scholar
  • 5 Danion F, Aguilar C, Catherinot E. , et al. Mucormycosis: new developments into a persistently devastating infection. Semin Respir Crit Care Med 2015; 36 (05) 692-705
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Kwon-Chung KJ. Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. Clin Infect Dis 2012; 54 (Suppl. 01) S8-S15
    CrossrefPubMedGoogle Scholar
  • 7 Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13 (02) 236-301
    CrossrefPubMedGoogle Scholar
  • 8 Pyrgos V, Shoham S, Walsh TJ. Pulmonary zygomycosis. Semin Respir Crit Care Med 2008; 29 (02) 111-120
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Lazar SP, Lukaszewicz JM, Persad KA, Reinhardt JF. Rhinocerebral Mucor circinelloides infection in immunocompromised patient following yogurt ingestion. Del Med J 2014; 86 (08) 245-248
    PubMedGoogle Scholar
  • 10 Lee SC, Billmyre RB, Li A. , et al. Analysis of a food-borne fungal pathogen outbreak: virulence and genome of a Mucor circinelloides isolate from yogurt. MBio 2014; 5 (04) e01390-e14
    PubMedGoogle Scholar
  • 11 Antoniadou A. Outbreaks of zygomycosis in hospitals. Clin Microbiol Infect 2009; 15 (Suppl. 05) 55-59
    PubMedGoogle Scholar
  • 12 Sipsas NV, Kontoyiannis DP. Occupation, lifestyle, diet, and invasive fungal infections. Infection 2008; 36 (06) 515-525
    CrossrefPubMedGoogle Scholar
  • 13 Lelievre L, Garcia-Hermoso D, Abdoul H. , et al; French Mycosis Study Group. Posttraumatic mucormycosis: a nationwide study in France and review of the literature. Medicine (Baltimore) 2014; 93 (24) 395-404
    PubMedGoogle Scholar
  • 14 Moreira J, Varon A, Galhardo MC. , et al. The burden of mucormycosis in HIV-infected patients: a systematic review. J Infect 2016; 73 (03) 181-188
    CrossrefPubMedGoogle Scholar
  • 15 Roden MM, Zaoutis TE, Buchanan WL. , et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41 (05) 634-653
    CrossrefPubMedGoogle Scholar
  • 16 Radner AB, Witt MD, Edwards Jr JE. Acute invasive rhinocerebral zygomycosis in an otherwise healthy patient: case report and review. Clin Infect Dis 1995; 20 (01) 163-166
    CrossrefPubMedGoogle Scholar
  • 17 Nasa M, Sharma Z, Lipi L, Sud R. Gastric angioinvasive mucormycosis in immunocompetent adult, a rare occurrence. J Assoc Physicians India 2017; 65 (12) 103-104
    PubMedGoogle Scholar
  • 18 Wang Y, Zhu M, Bao Y. , et al. Cutaneous mucormycosis caused by Rhizopus microsporus in an immunocompetent patient: a case report and review of literature. Medicine (Baltimore) 2018; 97 (25) e11141
    PubMedGoogle Scholar
  • 19 Park BJ, Pappas PG, Wannemuehler KA. , et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis 2011; 17 (10) 1855-1864
    CrossrefPubMedGoogle Scholar
  • 20 Jeong W, Keighley C, Wolfe R. , et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect 2019; 25 (01) 26-34
    CrossrefPubMedGoogle Scholar
  • 21 Kontoyianis DP, Vartivarian S, Anaissie EJ, Samonis G, Bodey GP, Rinaldi M. Infections due to Cunninghamella bertholletiae in patients with cancer: report of three cases and review. Clin Infect Dis 1994; 18 (06) 925-928
    CrossrefPubMedGoogle Scholar
  • 22 Gomes MZ, Lewis RE, Kontoyiannis DP. Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species. Clin Microbiol Rev 2011; 24 (02) 411-445
    CrossrefPubMedGoogle Scholar
  • 23 Hamilos G, Samonis G, Kontoyiannis DP. Pulmonary mucormycosis. Semin Respir Crit Care Med 2011; 32 (06) 693-702
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Spellberg B, Edwards Jr J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005; 18 (03) 556-569
    CrossrefPubMedGoogle Scholar
  • 25 Rodríguez JY, Morales-López SE, Rodríguez GJ. , et al. Necrotizing fasciitis caused by Apophysomyces variabilis in an immunocompetent patient. Med Mycol Case Rep 2017; 20: 4-6
    PubMedGoogle Scholar
  • 26 Prakash H, Ghosh AK, Rudramurthy SM. , et al. The environmental source of emerging Apophysomyces variabilis infection in India. Med Mycol 2016; 54 (06) 567-575
    CrossrefPubMedGoogle Scholar
  • 27 Bonifaz A, Stchigel AM, Guarro J. , et al. Primary cutaneous mucormycosis produced by the new species Apophysomyces mexicanus . J Clin Microbiol 2014; 52 (12) 4428-4431
    CrossrefPubMedGoogle Scholar
  • 28 Guarro J, Chander J, Alvarez E. , et al. Apophysomyces variabilis infections in humans. Emerg Infect Dis 2011; 17 (01) 134-135
    CrossrefPubMedGoogle Scholar
  • 29 Vilela R, Mendoza L. Human pathogenic entomophthorales. Clin Microbiol Rev 2018; 31 (04) 31
    CrossrefPubMedGoogle Scholar
  • 30 Tilak R, Raina P, Gupta SK, Tilak V, Prakash P, Gulati AK. Cutaneous zygomycosis: a possible postoperative complication in immunocompetent individuals. Indian J Dermatol Venereol Leprol 2009; 75 (06) 596-599
    CrossrefPubMedGoogle Scholar
  • 31 Gamarra S, Chaves MS, Cabeza MS. , et al. Mucormycosis outbreak due to Rhizopus microsporus after arthroscopic anterior cruciate ligament reconstruction surgery evaluated by RAPD and MALDI-TOF Mass spectrometry. J Mycol Med 2018; 28 (04) 617-622
    CrossrefPubMedGoogle Scholar
  • 32 Kontoyiannis DP, Lewis RE. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am 2006; 20 (03) 581-607 , vi
    CrossrefPubMedGoogle Scholar
  • 33 Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis 2012; 54 (Suppl. 01) S16-S22
    CrossrefPubMedGoogle Scholar
  • 34 Chamilos G, Lewis RE, Lamaris G, Walsh TJ, Kontoyiannis DP. Zygomycetes hyphae trigger an early, robust proinflammatory response in human polymorphonuclear neutrophils through toll-like receptor 2 induction but display relative resistance to oxidative damage. Antimicrob Agents Chemother 2008; 52 (02) 722-724
    CrossrefPubMedGoogle Scholar
  • 35 Ibrahim AS, Kontoyiannis DP. Update on mucormycosis pathogenesis. Curr Opin Infect Dis 2013; 26 (06) 508-515
    CrossrefPubMedGoogle Scholar
  • 36 Petrikkos G, Tsioutis C. Recent advances in the pathogenesis of mucormycoses. Clin Ther 2018; 40 (06) 894-902
    CrossrefPubMedGoogle Scholar
  • 37 Ibrahim AS, Gebremariam T, Lin L. , et al. The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis. Mol Microbiol 2010; 77 (03) 587-604
    CrossrefPubMedGoogle Scholar
  • 38 Boelaert JR, de Locht M, Van Cutsem J. , et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest 1993; 91 (05) 1979-1986
    CrossrefPubMedGoogle Scholar
  • 39 Artis WM, Patrusky E, Rastinejad F, Duncan Jr RL. Fungistatic mechanism of human transferrin for Rhizopus oryzae and Trichophyton mentagrophytes: alternative to simple iron deprivation. Infect Immun 1983; 41 (03) 1269-1278
    CrossrefPubMedGoogle Scholar
  • 40 Liu M, Spellberg B, Phan QT. , et al. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest 2010; 120 (06) 1914-1924
    CrossrefPubMedGoogle Scholar
  • 41 Ibrahim AS. Host-iron assimilation: pathogenesis and novel therapies of mucormycosis. Mycoses 2014; 57 (Suppl. 03) 13-17
    CrossrefPubMedGoogle Scholar
  • 42 Bitar D, Lortholary O, Le Strat Y. , et al. Population-based analysis of invasive fungal infections, France, 2001-2010. Emerg Infect Dis 2014; 20 (07) 1149-1155
    CrossrefPubMedGoogle Scholar
  • 43 Bitar D, Van Cauteren D, Lanternier F. , et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis 2009; 15 (09) 1395-1401
    CrossrefPubMedGoogle Scholar
  • 44 Saegeman V, Maertens J, Meersseman W, Spriet I, Verbeken E, Lagrou K. Increasing incidence of mucormycosis in University Hospital, Belgium. Emerg Infect Dis 2010; 16 (09) 1456-1458
    CrossrefPubMedGoogle Scholar
  • 45 Ambrosioni J, Bouchuiguir-Wafa K, Garbino J. Emerging invasive zygomycosis in a tertiary care center: epidemiology and associated risk factors. Int J Infect Dis 2010; 14 (Suppl. 03) e100-e103
    PubMedGoogle Scholar
  • 46 Guinea J, Escribano P, Vena A. , et al. Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: epidemiology and microbiological characterization of the isolates. PLoS One 2017; 12 (06) e0179136
    CrossrefPubMedGoogle Scholar
  • 47 Pagano L, Caira M, Nosari A. , et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007; 45 (09) 1161-1170
    CrossrefPubMedGoogle Scholar
  • 48 Siwek GT, Dodgson KJ, de Magalhaes-Silverman M. , et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004; 39 (04) 584-587
    CrossrefPubMedGoogle Scholar
  • 49 Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39 (05) 743-746
    CrossrefPubMedGoogle Scholar
  • 50 Trifilio SM, Bennett CL, Yarnold PR. , et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007; 39 (07) 425-429
    CrossrefPubMedGoogle Scholar
  • 51 Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350 (09) 950-952
    CrossrefPubMedGoogle Scholar
  • 52 Singh N, Aguado JM, Bonatti H. , et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis 2009; 200 (06) 1002-1011
    CrossrefPubMedGoogle Scholar
  • 53 Lamoth F, Chung SJ, Damonti L, Alexander BD. Changing epidemiology of invasive mold infections in patients receiving azole prophylaxis. Clin Infect Dis 2017; 64 (11) 1619-1621
    CrossrefPubMedGoogle Scholar
  • 54 Pongas GN, Lewis RE, Samonis G, Kontoyiannis DP. Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices?. Clin Microbiol Infect 2009; 15 (Suppl. 05) 93-97
    PubMedGoogle Scholar
  • 55 Arendrup MC, Jensen RH, Meletiadis J. In vitro activity of isavuconazole and comparators against clinical isolates of the Mucorales order. Antimicrob Agents Chemother 2015; 59 (12) 7735-7742
    CrossrefPubMedGoogle Scholar
  • 56 Webb BJ, Ferraro JP, Rea S, Kaufusi S, Goodman BE, Spalding J. Epidemiology and clinical features of invasive fungal infection in a US Health Care Network. Open Forum Infect Dis 2018; 5 (08) ofy187
    CrossrefPubMedGoogle Scholar
  • 57 Kontoyiannis DP, Yang H, Song J. , et al. Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study. BMC Infect Dis 2016; 16 (01) 730
    CrossrefPubMedGoogle Scholar
  • 58 Zilberberg MD, Shorr AF, Huang H, Chaudhari P, Paly VF, Menzin J. Hospital days, hospitalization costs, and inpatient mortality among patients with mucormycosis: a retrospective analysis of US hospital discharge data. BMC Infect Dis 2014; 14: 310
    CrossrefPubMedGoogle Scholar
  • 59 Kennedy KJ, Daveson K, Slavin MA. , et al; Australia and New Zealand Mycoses Interest Group of the Australasian Society for Infectious Diseases. Mucormycosis in Australia: contemporary epidemiology and outcomes. Clin Microbiol Infect 2016; 22 (09) 775-781
    CrossrefPubMedGoogle Scholar
  • 60 Elgarten CW, Levy EM, Mattei P, Fisher BT, Olson TS, Freedman JL. Successful treatment of pulmonary mucormycosis in two pediatric hematopoietic stem cell transplant patients. Pediatr Transplant 2018; 22 (07) e13270
    CrossrefPubMedGoogle Scholar
  • 61 Pana ZD, Seidel D, Skiada A. , et al; Collaborators of Zygomyco.net and/or FungiScope™ Registries*. Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries. BMC Infect Dis 2016; 16 (01) 667
    CrossrefPubMedGoogle Scholar
  • 62 Hopkins MA, Treloar DM. Mucormycosis in diabetes. Am J Crit Care 1997; 6 (05) 363-367
    CrossrefPubMedGoogle Scholar
  • 63 Safar A, Marsan J, Marglani O, Al-Sebeih K, Al-Harbi J, Valvoda M. Early identification of rhinocerebral mucormycosis. J Otolaryngol 2005; 34 (03) 166-171
    CrossrefPubMedGoogle Scholar
  • 64 Saedi B, Sadeghi M, Seilani P. Endoscopic management of rhinocerebral mucormycosis with topical and intravenous amphotericin B. J Laryngol Otol 2011; 125 (08) 807-810
    CrossrefPubMedGoogle Scholar
  • 65 Kontoyiannis DP, Lionakis MS, Lewis RE. , et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191 (08) 1350-1360
    CrossrefPubMedGoogle Scholar
  • 66 Dimaka K, Mallis A, Naxakis SS. , et al. Chronic rhinocerebral mucormycosis: a rare case report and review of the literature. Mycoses 2014; 57 (11) 699-702
    CrossrefPubMedGoogle Scholar
  • 67 Prakash H, Ghosh AK, Rudramurthy SM. , et al. A prospective multicenter study on mucormycosis in India: epidemiology, diagnosis, and treatment. Med Mycol 2019; 57 (04) 395-402
    CrossrefPubMedGoogle Scholar
  • 68 Chretien ML, Legouge C, Pagès PB. , et al. Emergency and elective pulmonary surgical resection in haematological patients with invasive fungal infections: a report of 50 cases in a single centre. Clin Microbiol Infect 2016; 22 (09) 782-787
    CrossrefPubMedGoogle Scholar
  • 69 Chamilos G, Luna M, Lewis RE. , et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006; 91 (07) 986-989
    PubMedGoogle Scholar
  • 70 Lanternier F, Dannaoui E, Morizot G. , et al; French Mycosis Study Group. A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). Clin Infect Dis 2012; 54 (Suppl. 01) S35-S43
    CrossrefPubMedGoogle Scholar
  • 71 Gleissner B, Schilling A, Anagnostopolous I, Siehl I, Thiel E. Improved outcome of zygomycosis in patients with hematological diseases?. Leuk Lymphoma 2004; 45 (07) 1351-1360
    CrossrefPubMedGoogle Scholar
  • 72 Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008; 47 (04) 503-509
    CrossrefPubMedGoogle Scholar
  • 73 Hammond SP, Baden LR, Marty FM. Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis, 2001 to 2009. Antimicrob Agents Chemother 2011; 55 (11) 5018-5021
    CrossrefPubMedGoogle Scholar
  • 74 Skiada A, Pagano L, Groll A. , et al; European Confederation of Medical Mycology Working Group on Zygomycosis. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011; 17 (12) 1859-1867
    CrossrefPubMedGoogle Scholar
  • 75 Lanternier F, Sun HY, Ribaud P, Singh N, Kontoyiannis DP, Lortholary O. Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis 2012; 54 (11) 1-8
    PubMedGoogle Scholar
  • 76 Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34 (07) 909-917
    CrossrefPubMedGoogle Scholar
  • 77 Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008; 47 (08) 1041-1050
    CrossrefPubMedGoogle Scholar
  • 78 Lee JH, Hyun JS, Kang DY, Lee HJ, Park SG. Rare complication of bronchoesophageal fistula due to pulmonary mucormycosis after induction chemotherapy for acute myeloid leukemia: a case report. J Med Case Reports 2016; 10: 195
    CrossrefPubMedGoogle Scholar
  • 79 Chitasombat MN, Kontoyiannis DP. Treatment of mucormycosis in transplant patients: role of surgery and of old and new antifungal agents. Curr Opin Infect Dis 2016; 29 (04) 340-345
    CrossrefPubMedGoogle Scholar
  • 80 Davari HR, Malekhossini SA, Salahi HA. , et al. Outcome of mucormycosis in liver transplantation: four cases and a review of literature. Exp Clin Transplant 2003; 1 (02) 147-152
    PubMedGoogle Scholar
  • 81 Husain S, Silveira FP, Azie N, Franks B, Horn D. Epidemiological features of invasive mold infections among solid organ transplant recipients: PATH Alliance® registry analysis. Med Mycol 2017; 55 (03) 269-277
    PubMedGoogle Scholar
  • 82 Almyroudis NG, Sutton DA, Linden P, Rinaldi MG, Fung J, Kusne S. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant 2006; 6 (10) 2365-2374
    CrossrefPubMedGoogle Scholar
  • 83 Kreiniz N, Bejar J, Polliack A, Tadmor T. Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma. Hematol Oncol 2018; 36 (01) 349-354
    CrossrefPubMedGoogle Scholar
  • 84 Arce-Salinas CA, Pérez-Silva E. Mucormycosis complications in systemic lupus erythematosus. Lupus 2010; 19 (08) 985-988
    CrossrefPubMedGoogle Scholar
  • 85 Weng DE, Wilson WH, Little R, Walsh TJ. Successful medical management of isolated renal zygomycosis: case report and review. Clin Infect Dis 1998; 26 (03) 601-605
    CrossrefPubMedGoogle Scholar
  • 86 Moreira J, Ridolfi F, Almeida-Paes R, Varon A, Lamas CC. Cutaneous mucormycosis in advanced HIV disease. Braz J Infect Dis 2016; 20 (06) 637-640
    CrossrefPubMedGoogle Scholar
  • 87 Ahmed Y, Delaney S, Markarian A. Successful isavuconazole therapy in a patient with acute invasive fungal rhinosinusitis and acquired immune deficiency syndrome. Am J Otolaryngol 2016; 37 (02) 152-155
    CrossrefPubMedGoogle Scholar
  • 88 Kutlu M, Ergin C, Bir F. , et al. Pulmonary mucormycosis due to Lichtheimia ramosa in a patient with HIV infection. Mycopathologia 2014; 178 (1-2): 111-115
    CrossrefPubMedGoogle Scholar
  • 89 Rathi M, Sengupta U, Yadav TD, Kumar S. Zygomycetes peritonitis in ambulatory peritoneal dialysis: case report and review of literature. Indian J Nephrol 2014; 24 (04) 252-254
    CrossrefPubMedGoogle Scholar
  • 90 Ram R, Swarnalatha G, Prasad N, Dakshinamurty KV. Exit site infection due to zygomycosis resulting in abdominal wall necrosis in a continuous ambulatory peritoneal dialysis patient. Nephrol Dial Transplant 2007; 22 (01) 266-267
    PubMedGoogle Scholar
  • 91 Sedlacek M, Cotter JG, Suriawinata AA. , et al. Mucormycosis peritonitis: more than 2 years of disease-free follow-up after posaconazole salvage therapy after failure of liposomal amphotericin B. Am J Kidney Dis 2008; 51 (02) 302-306
    CrossrefPubMedGoogle Scholar
  • 92 Serna JH, Wanger A, Dosekun AK. Successful treatment of mucormycosis peritonitis with liposomal amphotericin B in a patient on long-term peritoneal dialysis. Am J Kidney Dis 2003; 42 (03) E14-E17
    PubMedGoogle Scholar
  • 93 Reed C, Ibrahim A, Edwards Jr JE, Walot I, Spellberg B. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother 2006; 50 (11) 3968-3969
    CrossrefPubMedGoogle Scholar
  • 94 Stern LE, Kagan RJ. Rhinocerebral mucormycosis in patients with burns: case report and review of the literature. J Burn Care Rehabil 1999; 20 (04) 303-306
    CrossrefPubMedGoogle Scholar
  • 95 Chander J, Singla N, Kaur M. , et al. Saksenaea erythrospora, an emerging mucoralean fungus causing severe necrotizing skin and soft tissue infections - a study from a tertiary care hospital in north India. Infect Dis (Lond) 2017; 49 (03) 170-177
    CrossrefPubMedGoogle Scholar
  • 96 Warkentien T, Rodriguez C, Lloyd B. , et al; Infectious Disease Clinical Research Program Trauma Infectious Disease Outcomes Study Group. Invasive mold infections following combat-related injuries. Clin Infect Dis 2012; 55 (11) 1441-1449
    CrossrefPubMedGoogle Scholar
  • 97 Tyll T, Lyskova P, Hubka V. , et al. Early diagnosis of cutaneous mucormycosis due to Lichtheimia corymbifera after a traffic accident. Mycopathologia 2016; 181 (1-2): 119-124
    CrossrefPubMedGoogle Scholar
  • 98 Venkatesh D, Dandagi S, Chandrappa PR, Hema KN. Mucormycosis in immunocompetent patient resulting in extensive maxillary sequestration. J Oral Maxillofac Pathol 2018; 22 (Suppl. 01) S112-S116
    CrossrefPubMedGoogle Scholar
  • 99 Chakrabarti A, Singh R. Mucormycosis in India: unique features. Mycoses 2014; 57 (Suppl. 03) 85-90
    CrossrefPubMedGoogle Scholar
  • 100 Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 1999; 26 (3-4): 259-265
    CrossrefPubMedGoogle Scholar
  • 101 Rapidis AD. Orbitomaxillary mucormycosis (zygomycosis) and the surgical approach to treatment: perspectives from a maxillofacial surgeon. Clin Microbiol Infect 2009; 15 (Suppl. 05) 98-102
    PubMedGoogle Scholar
  • 102 Kontoyiannis DP, Marr KA, Park BJ. , et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50 (08) 1091-1100
    CrossrefPubMedGoogle Scholar
  • 103 Neofytos D, Treadway S, Ostrander D. , et al. Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience. Transpl Infect Dis 2013; 15 (03) 233-242
    CrossrefPubMedGoogle Scholar
  • 104 Riches ML, Trifilio S, Chen M. , et al. Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: a CIBMTR infection and immune reconstitution analysis. Bone Marrow Transplant 2016; 51 (02) 277-282
    CrossrefPubMedGoogle Scholar
  • 105 Sun HY, Aguado JM, Bonatti H. , et al; Zygomycosis Transplant Study Group. Pulmonary zygomycosis in solid organ transplant recipients in the current era. Am J Transplant 2009; 9 (09) 2166-2171
    CrossrefPubMedGoogle Scholar
  • 106 Song Y, Qiao J, Giovanni G. , et al. Mucormycosis in renal transplant recipients: review of 174 reported cases. BMC Infect Dis 2017; 17 (01) 283
    CrossrefPubMedGoogle Scholar
  • 107 Guimarães LF, Halpern M, de Lemos AS. , et al. Invasive fungal disease in renal transplant recipients at a Brazilian center: local epidemiology matters. Transplant Proc 2016; 48 (07) 2306-2309
    CrossrefPubMedGoogle Scholar
  • 108 Rabin AS, Givertz MM, Couper GS. , et al. Risk factors for invasive fungal disease in heart transplant recipients. J Heart Lung Transplant 2015; 34 (02) 227-232
    CrossrefPubMedGoogle Scholar
  • 109 Abboud CS, Bergamasco MD, Baía CE. , et al. Case report of hepatic mucormycosis after liver transplantation: successful treatment with liposomal amphotericin B followed by posaconazole sequential therapy. Transplant Proc 2012; 44 (08) 2501-2502
    CrossrefPubMedGoogle Scholar
  • 110 Deyo JC, Nicolsen N, Lachiewicz A, Kozlowski T. Salvage Treatment of Mucormycosis Post-Liver Transplant With Posaconazole During Sirolimus Maintenance Immunosuppression. J Pharm Pract 2017; 30 (02) 261-265
    CrossrefPubMedGoogle Scholar
  • 111 Do GW, Jung SW, Jun JB, Seo JH, Nah YW. Colonic mucormycosis presented with ischemic colitis in a liver transplant recipient. World J Gastroenterol 2013; 19 (22) 3508-3511
    CrossrefPubMedGoogle Scholar
  • 112 Ramos A, Cuervas-Mons V, Noblejas A. , et al. Breakthrough rhinocerebral mucormycosis in a liver transplant patient receiving caspofungin. Transplant Proc 2009; 41 (05) 1972-1975
    CrossrefPubMedGoogle Scholar
  • 113 Vondran FW, Knitsch W, Krech T. , et al. Intestinal mucormycosis with Rhizopus microsporus after liver transplantation--successful treatment of a rare but life-threatening complication. Transplantation 2014; 97 (02) e11-e13
    CrossrefPubMedGoogle Scholar
  • 114 García-Pajares F, Sánchez-Antolín G, Almohalla Alvárez C. , et al. Cutaneous mucormycosis infection by Absidia in two consecutive liver transplant patients. Transplant Proc 2012; 44 (06) 1562-1564
    CrossrefPubMedGoogle Scholar
  • 115 Farojov R, Aydın O, Yılmaz C. , et al. Rhino-orbita-maxillary mucormycosis after liver transplantation: a case report. Transplant Proc 2016; 48 (09) 3210-3213
    CrossrefPubMedGoogle Scholar
  • 116 Nam Y, Jung J, Park SS. , et al. Disseminated mucormycosis with myocardial involvement in a renal transplant recipient. Transpl Infect Dis 2015; 17 (06) 890-896
    CrossrefPubMedGoogle Scholar
  • 117 Tan M, Gibney EM. Lung mass in a kidney transplant recipient. Am J Transplant 2015; 15 (01) 281-282 , quiz 283
    CrossrefPubMedGoogle Scholar
  • 118 Davuodi S, Manshadi SA, Salehi MR, Yazdi F, Khazravi M, Fazli JT. Fatal cutaneous mucormycosis after kidney transplant. Exp Clin Transplant 2015; 13 (01) 82-85
    PubMedGoogle Scholar
  • 119 Ville S, Talarmin JP, Gaultier-Lintia A. , et al. Disseminated mucormycosis with cerebral involvement owing to Rhizopus microsporus in a kidney recipient treated with combined liposomal amphotericin B and posaconazole therapy. Exp Clin Transplant 2016; 14 (01) 96-99
    PubMedGoogle Scholar
  • 120 Barnajian M, Gioia W, Iordache F, Bergamaschi R. Mucormycosis-induced colon perforation after renal transplantation. Surg Infect (Larchmt) 2014; 15 (05) 665-666
    CrossrefPubMedGoogle Scholar
  • 121 Zhu X, Liu H, Wang W. , et al. Two cases of transplant renal artery thrombosis and spontaneous rupture caused by mucormycosis. Transpl Infect Dis 2015; 17 (03) 442-448
    CrossrefPubMedGoogle Scholar
  • 122 Tobón AM, Arango M, Fernández D, Restrepo A. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin Infect Dis 2003; 36 (11) 1488-1491
    CrossrefPubMedGoogle Scholar
  • 123 Navanukroh O, Jitmuang A, Chayakulkeeree M, Ngamskulrungroj P. Disseminated Cunninghamella bertholletiae infection with spinal epidural abscess in a kidney transplant patient: case report and literature review. Transpl Infect Dis 2014; 16 (04) 658-665
    CrossrefPubMedGoogle Scholar
  • 124 Park W, Jang M, Hwang E. , et al. Allograft mucormycosis due to Rhizopus microsporus in a kidney transplant recipient. Transplant Proc 2014; 46 (02) 623-625
    CrossrefPubMedGoogle Scholar
  • 125 Lee E, Vershvovsky Y, Miller F, Waltzer W, Suh H, Nord EP. Combined medical surgical therapy for pulmonary mucormycosis in a diabetic renal allograft recipient. Am J Kidney Dis 2001; 38 (06) E37
    CrossrefPubMedGoogle Scholar
  • 126 Tan HP, Razzouk A, Gundry SR, Bailey L. Pulmonary Rhizopus rhizopodiformis cavitary abscess in a cardiac allograft recipient. J Cardiovasc Surg (Torino) 1999; 40 (02) 223-226
    PubMedGoogle Scholar
  • 127 Kfoury AG, Smith JC, Farhoud HH. , et al. Adjuvant intrapleural amphotericin B therapy for pulmonary mucormycosis in a cardiac allograft recipient. Clin Transplant 1997; 11 (06) 608-612
    PubMedGoogle Scholar
  • 128 Zander DS, Cicale MJ, Mergo P. Durable cure of mucormycosis involving allograft and native lungs. J Heart Lung Transplant 2000; 19 (06) 615-618
    CrossrefPubMedGoogle Scholar
  • 129 Bhaskaran A, Hosseini-Moghaddam SM, Rotstein C, Husain S. Mold infections in lung transplant recipients. Semin Respir Crit Care Med 2013; 34 (03) 371-379
    Article in Thieme ConnectPubMedGoogle Scholar
  • 130 Page AV, Evans AJ, Snell L, Liles WC. Primary cutaneous mucormycosis in a lung transplant recipient: case report and concise review of the literature. Transpl Infect Dis 2008; 10 (06) 419-425
    CrossrefPubMedGoogle Scholar
  • 131 Silveira FP, Kwak EJ, Paterson DL, Pilewski JM, McCurry KR, Husain S. Post-transplant colonization with non-Aspergillus molds and risk of development of invasive fungal disease in lung transplant recipients. J Heart Lung Transplant 2008; 27 (08) 850-855
    CrossrefPubMedGoogle Scholar
  • 132 Frater JL, Hall GS, Procop GW. Histologic features of zygomycosis: emphasis on perineural invasion and fungal morphology. Arch Pathol Lab Med 2001; 125 (03) 375-378
    CrossrefPubMedGoogle Scholar
  • 133 Sharma S, Gupta P, Gupta N, Lal A, Behera D, Rajwanshi A. Pulmonary infections in immunocompromised patients: the role of image-guided fine needle aspiration cytology. Cytopathology 2017; 28 (01) 46-54
    CrossrefPubMedGoogle Scholar
  • 134 Haas BM, Clayton JD, Elicker BM, Ordovas KG, Naeger DM. CT-guided percutaneous lung biopsies in patients with suspicion for infection may yield clinically useful information. AJR Am J Roentgenol 2017; 208 (02) 459-463
    CrossrefPubMedGoogle Scholar
  • 135 Lass-Flörl C. Zygomycosis: conventional laboratory diagnosis. Clin Microbiol Infect 2009; 15 (Suppl. 05) 60-65
    PubMedGoogle Scholar
  • 136 Millon L, Herbrecht R, Grenouillet F. , et al; French Mycosis Study Group. Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF). Clin Microbiol Infect 2016; 22 (09) 810.e1-810.e8
    CrossrefPubMedGoogle Scholar
  • 137 Millon L, Larosa F, Lepiller Q. , et al. Quantitative polymerase chain reaction detection of circulating DNA in serum for early diagnosis of mucormycosis in immunocompromised patients. Clin Infect Dis 2013; 56 (10) e95-e101
    CrossrefPubMedGoogle Scholar
  • 138 Hata DJ, Buckwalter SP, Pritt BS, Roberts GD, Wengenack NL. Real-time PCR method for detection of zygomycetes. J Clin Microbiol 2008; 46 (07) 2353-2358
    CrossrefPubMedGoogle Scholar
  • 139 Rickerts V, Just-Nübling G, Konrad F. , et al. Diagnosis of invasive aspergillosis and mucormycosis in immunocompromised patients by seminested PCR assay of tissue samples. Eur J Clin Microbiol Infect Dis 2006; 25 (01) 8-13
    CrossrefPubMedGoogle Scholar
  • 140 Salehi E, Hedayati MT, Zoll J. , et al. Discrimination of aspergillosis, mucormycosis, fusariosis and scedosporiosis in formalin-fixed paraffin-embedded tissue specimens by use of multiple real-time quantitative PCR assays. J Clin Microbiol 2016; 54 (11) 2798-2803
    CrossrefPubMedGoogle Scholar
  • 141 Shigemura T, Nishina S, Nakazawa H, Matsuda K, Yaguchi T, Nakazawa Y. Early detection of Rhizopus DNA in the serum of a patient with rhino-orbital-cerebral mucormycosis following allogeneic hematopoietic stem cell transplantation. Int J Hematol 2016; 103 (03) 354-355
    CrossrefPubMedGoogle Scholar
  • 142 Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis 2012; 54 (Suppl. 01) S55-S60
    CrossrefPubMedGoogle Scholar
  • 143 Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, Roilides E, Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol 2018; 56 (suppl_1): 93-101
    CrossrefPubMedGoogle Scholar
  • 144 Hammond SP, Bialek R, Milner DA, Petschnigg EM, Baden LR, Marty FM. Molecular methods to improve diagnosis and identification of mucormycosis. J Clin Microbiol 2011; 49 (06) 2151-2153
    CrossrefPubMedGoogle Scholar
  • 145 Rickerts V, Mousset S, Lambrecht E. , et al. Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens. Clin Infect Dis 2007; 44 (08) 1078-1083
    CrossrefPubMedGoogle Scholar
  • 146 Bialek R, Konrad F, Kern J. , et al. PCR based identification and discrimination of agents of mucormycosis and aspergillosis in paraffin wax embedded tissue. J Clin Pathol 2005; 58 (11) 1180-1184
    CrossrefPubMedGoogle Scholar
  • 147 Lackner M, Caramalho R, Lass-Flörl C. Laboratory diagnosis of mucormycosis: current status and future perspectives. Future Microbiol 2014; 9 (05) 683-695
    CrossrefPubMedGoogle Scholar
  • 148 Gholinejad-Ghadi N, Shokohi T, Seifi Z. , et al. Identification of Mucorales in patients with proven invasive mucormycosis by polymerase chain reaction in tissue samples. Mycoses 2018; 61 (12) 909-915
    CrossrefPubMedGoogle Scholar
  • 149 Ling H, Yuan Z, Shen J, Wang Z, Xu Y. Accuracy of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of clinical pathogenic fungi: a meta-analysis. J Clin Microbiol 2014; 52 (07) 2573-2582
    CrossrefPubMedGoogle Scholar
  • 150 Blauwkamp TA, Thair S, Rosen MJ. , et al. Analytical and clinical validation of a microbial cell-free DNA sequencing test for infectious disease. Nat Microbiol 2019; 4 (04) 663-674
    CrossrefPubMedGoogle Scholar
  • 151 Sun HY, Forrest G, Gupta KL. , et al. Rhino-orbital-cerebral zygomycosis in solid organ transplant recipients. Transplantation 2010; 90 (01) 85-92
    PubMedGoogle Scholar
  • 152 Li H, Hwang SK, Zhou C, Du J, Zhang J. Gangrenous cutaneous mucormycosis caused by Rhizopus oryzae: a case report and review of primary cutaneous mucormycosis in China over past 20 years. Mycopathologia 2013; 176 (1-2): 123-128
    CrossrefPubMedGoogle Scholar
  • 153 Chan Y, Goldwater P, Saxon B. Successful treatment of cutaneous and subcutaneous zygomycosis in an immunosuppressed patient with aplastic anaemia. J Paediatr Child Health 2007; 43 (1-2): 87-89
    CrossrefPubMedGoogle Scholar
  • 154 Tathe SP, Dani AA, Chawhan SM, Meshram SA, Randale AA, Raut WK. Gastric mucormycosis: diagnosis by imprint cytology. Diagn Cytopathol 2016; 44 (10) 820-822
    CrossrefPubMedGoogle Scholar
  • 155 Bernardo RM, Gurung A, Jain D, Malinis MF. Therapeutic challenges of hepatic mucormycosis in hematologic malignancy: a case report and review of the literature. Am J Case Rep 2016; 17: 484-489
    CrossrefPubMedGoogle Scholar
  • 156 Manesh A, John AO, Mathew B. , et al. Posaconazole: an emerging therapeutic option for invasive rhino-orbito-cerebral mucormycosis. Mycoses 2016; 59 (12) 765-772
    CrossrefPubMedGoogle Scholar
  • 157 Giudice G, Cutrignelli DA, Sportelli P. , et al. Rhinocerebral mucormycosis with orosinusal involvement: diagnostic and surgical treatment guidelines. Endocr Metab Immune Disord Drug Targets 2016; 16 (04) 264-269
    PubMedGoogle Scholar
  • 158 Nezafati S, Kazemi A, Asgari K, Bahrami A, Naghili B, Yazdani J. Rhinocerebral mucormycosis, risk factors and the type of oral manifestations in patients referred to a University Hospital in Tabriz, Iran 2007-2017. Mycoses 2018; 61 (10) 764-769
    CrossrefPubMedGoogle Scholar
  • 159 Prabhu S, Alqahtani M, Al Shehabi M. A fatal case of rhinocerebral mucormycosis of the jaw after dental extractions and review of literature. J Infect Public Health 2018; 11 (03) 301-303
    CrossrefPubMedGoogle Scholar
  • 160 Aras MH, Kara MI, Erkiliç S, Ay S. Mandibular mucormycosis in immunocompromised patients: report of 2 cases and review of the literature. J Oral Maxillofac Surg 2012; 70 (06) 1362-1368
    CrossrefPubMedGoogle Scholar
  • 161 Huang JS, Kok SH, Lee JJ, Hsu WY, Chiang CP, Kuo YS. Extensive maxillary sequestration resulting from mucormycosis. Br J Oral Maxillofac Surg 2005; 43 (06) 532-534
    CrossrefPubMedGoogle Scholar
  • 162 Augustine HFM, White C, Bain J. Aggressive combined medical and surgical management of mucormycosis results in disease eradication in 2 pediatric patients. Plast Surg (Oakv) 2017; 25 (03) 211-217
    CrossrefPubMedGoogle Scholar
  • 163 Mattingly JK, Ramakrishnan VR. Rhinocerebral mucormycosis of the optic nerve. Otolaryngol Head Neck Surg 2016; 155 (05) 888-889
    CrossrefPubMedGoogle Scholar
  • 164 Vogt N, Heß K, Bialek R. , et al. Epileptic seizures and rhinocerebral mucormycosis during blinatumomab treatment in a patient with biphenotypic acute leukemia. Ann Hematol 2017; 96 (01) 151-153
    CrossrefPubMedGoogle Scholar
  • 165 Palejwala SK, Zangeneh TT, Goldstein SA, Lemole GM. An aggressive multidisciplinary approach reduces mortality in rhinocerebral mucormycosis. Surg Neurol Int 2016; 7: 61
    PubMedGoogle Scholar
  • 166 Mulki R, Masab M, Eiger G, Perloff S. Lethargy and vision loss: successful management of rhinocerebral mucormycosis. BMJ Case Rep 2016; 2016: bcr2016215855
    PubMedGoogle Scholar
  • 167 Andrey DO, Kaiser L, Emonet S, Erard V, Chalandon Y, van Delden C. Cerebral rhizomucor infection treated by posaconazole delayed-release tablets in an allogeneic stem cell transplant recipient. Int J Infect Dis 2017; 55: 24-26
    CrossrefPubMedGoogle Scholar
  • 168 Cornely OA, Arikan-Akdagli S, Dannaoui E. , et al; European Society of Clinical Microbiology and Infectious Diseases Fungal Infection Study Group; European Confederation of Medical Mycology. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 2014; 20 (Suppl. 03) 5-26
    PubMedGoogle Scholar
  • 169 Skiada A, Lanternier F, Groll AH. , et al; European Conference on Infections in Leukemia. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica 2013; 98 (04) 492-504
    CrossrefPubMedGoogle Scholar
  • 170 Greenberg RN, Mullane K, van Burik JA. , et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006; 50 (01) 126-133
    CrossrefPubMedGoogle Scholar
  • 171 Miceli MH, Kauffman CA. Isavuconazole: a new broad-spectrum triazole antifungal agent. Clin Infect Dis 2015; 61 (10) 1558-1565
    CrossrefPubMedGoogle Scholar
  • 172 Ananda-Rajah MR, Kontoyiannis D. Isavuconazole: a new extended spectrum triazole for invasive mold diseases. Future Microbiol 2015; 10 (05) 693-708
    CrossrefPubMedGoogle Scholar
  • 173 Jamadar DA, Kazerooni EA, Daly BD, White CS, Gross BH. Pulmonary zygomycosis: CT appearance. J Comput Assist Tomogr 1995; 19 (05) 733-738
    CrossrefPubMedGoogle Scholar
  • 174 Nam BD, Kim TJ, Lee KS, Kim TS, Han J, Chung MJ. Pulmonary mucormycosis: serial morphologic changes on computed tomography correlate with clinical and pathologic findings. Eur Radiol 2018; 28 (02) 788-795
    CrossrefPubMedGoogle Scholar
  • 175 Hammer MM, Madan R, Hatabu H. Pulmonary mucormycosis: radiologic features at presentation and over time. AJR Am J Roentgenol 2018; 210 (04) 742-747
    CrossrefPubMedGoogle Scholar
  • 176 Jung J, Kim MY, Lee HJ. , et al. Comparison of computed tomographic findings in pulmonary mucormycosis and invasive pulmonary aspergillosis. Clin Microbiol Infect 2015; 21 (07) 684.e11-684.e18
    CrossrefPubMedGoogle Scholar
  • 177 Dykhuizen RS, Kerr KN, Soutar RL. Air crescent sign and fatal haemoptysis in pulmonary mucormycosis. Scand J Infect Dis 1994; 26 (04) 498-501
    CrossrefPubMedGoogle Scholar
  • 178 Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 2005; 41 (01) 60-66
    CrossrefPubMedGoogle Scholar
  • 179 McAdams HP, Rosado de Christenson M, Strollo DC, Patz Jr EF. Pulmonary mucormycosis: radiologic findings in 32 cases. AJR Am J Roentgenol 1997; 168 (06) 1541-1548
    CrossrefPubMedGoogle Scholar
  • 180 Coffey MJ, Fantone III J, Stirling MC, Lynch III JP. Pseudoaneurysm of pulmonary artery in mucormycosis. Radiographic characteristics and management. Am Rev Respir Dis 1992; 145 (06) 1487-1490
    CrossrefPubMedGoogle Scholar
  • 181 Kitabayashi A, Hirokawa M, Yamaguchi A, Takatsu H, Miura AB. Invasive pulmonary mucormycosis with rupture of the thoracic aorta. Am J Hematol 1998; 58 (04) 326-329
    CrossrefPubMedGoogle Scholar
  • 182 Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg 1994; 57 (04) 1044-1050
    CrossrefPubMedGoogle Scholar
  • 183 Gupta KL, Khullar DK, Behera D, Radotra BD, Sakhuja V. Pulmonary mucormycosis presenting as fatal massive haemoptysis in a renal transplant recipient. Nephrol Dial Transplant 1998; 13 (12) 3258-3260
    CrossrefPubMedGoogle Scholar
  • 184 Grossi P, Farina C, Fiocchi R, Dalla Gasperina D. ; Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients. Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: a multicenter retrospective study. Transplantation 2000; 70 (01) 112-116
    PubMedGoogle Scholar
  • 185 Wahba H, Truong MT, Lei X, Kontoyiannis DP, Marom EM. Reversed halo sign in invasive pulmonary fungal infections. Clin Infect Dis 2008; 46 (11) 1733-1737
    CrossrefPubMedGoogle Scholar
  • 186 Legouge C, Caillot D, Chrétien ML. , et al. The reversed halo sign: pathognomonic pattern of pulmonary mucormycosis in leukemic patients with neutropenia?. Clin Infect Dis 2014; 58 (05) 672-678
    CrossrefPubMedGoogle Scholar
  • 187 Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis DP. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis 2011; 52 (09) 1144-1155
    CrossrefPubMedGoogle Scholar
  • 188 Choo JY, Park CM, Lee HJ, Lee CH, Goo JM, Im JG. Sequential morphological changes in follow-up CT of pulmonary mucormycosis. Diagn Interv Radiol 2014; 20 (01) 42-46
    PubMedGoogle Scholar
  • 189 Stanzani M, Battista G, Sassi C. , et al. Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies. Clin Infect Dis 2012; 54 (05) 610-616
    CrossrefPubMedGoogle Scholar
  • 190 Mills SEA, Yeldandi AV, Odell DD. Surgical treatment of multifocal pulmonary mucormycosis. Ann Thorac Surg 2018; 106 (02) e93-e95
    CrossrefPubMedGoogle Scholar
  • 191 Vercillo MS, Liptay MJ, Seder CW. Early pneumonectomy for pulmonary mucormycosis. Ann Thorac Surg 2015; 99 (03) e67-e68
    CrossrefPubMedGoogle Scholar
  • 192 Lin CY, Liu WL, Chang CC. , et al. Invasive fungal tracheobronchitis in mechanically ventilated critically ill patients: underlying conditions, diagnosis, and outcomes. Ann Intensive Care 2017; 7 (01) 9
    CrossrefPubMedGoogle Scholar
  • 193 Lewis RE, Georgiadou SP, Sampsonas F, Chamilos G, Kontoyiannis DP. Risk factors for early mortality in haematological malignancy patients with pulmonary mucormycosis. Mycoses 2014; 57 (01) 49-55
    CrossrefPubMedGoogle Scholar
  • 194 de Oliveira-Neto MP, Da Silva M, Fialho Monteiro PC. , et al. Cutaneous mucormycosis in a young, immunocompetent girl. Med Mycol 2006; 44 (06) 567-570
    CrossrefPubMedGoogle Scholar
  • 195 Ingram PR, Suthananthan AE, Rajan R. , et al. Cutaneous mucormycosis and motor vehicle accidents: findings from an Australian case series. Med Mycol 2014; 52 (08) 819-825
    CrossrefPubMedGoogle Scholar
  • 196 Matsudate Y, Murao K, Urano Y. , et al. Primary cutaneous mucormycosis caused by Mucor irregularis in an immunocompetent patient. J Dermatol 2015; 42 (03) 267-268
    CrossrefPubMedGoogle Scholar
  • 197 Lu XL, Liu ZH, Shen YN. , et al. Primary cutaneous zygomycosis caused by Rhizomucor variabilis: a new endemic zygomycosis? A case report and review of 6 cases reported from China. Clin Infect Dis 2009; 49 (03) e39-e43
    CrossrefPubMedGoogle Scholar
  • 198 Ledgard JP, van Hal S, Greenwood JE. Primary cutaneous zygomycosis in a burns patient: a review. J Burn Care Res 2008; 29 (02) 286-290
    CrossrefPubMedGoogle Scholar
  • 199 Neblett Fanfair R, Benedict K, Bos J. , et al. Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011. N Engl J Med 2012; 367 (23) 2214-2225
    CrossrefPubMedGoogle Scholar
  • 200 Snell BJ, Tavakoli K. Necrotizing fasciitis caused by Apophysomyces elegans complicating soft-tissue and pelvic injuries in a tsunami survivor from Thailand. Plast Reconstr Surg 2007; 119 (01) 448-449
    CrossrefPubMedGoogle Scholar
  • 201 Austin CL, Finley PJ, Mikkelson DR, Tibbs B. Mucormycosis: a rare fungal infection in tornado victims. J Burn Care Res 2014; 35 (03) e164-e171
    CrossrefPubMedGoogle Scholar
  • 202 Hicks Jr WL, Nowels K, Troxel J. Primary cutaneous mucormycosis. Am J Otolaryngol 1995; 16 (04) 265-268
    CrossrefPubMedGoogle Scholar
  • 203 Lechevalier P, Hermoso DG, Carol A. , et al. Molecular diagnosis of Saksenaea vasiformis cutaneous infection after scorpion sting in an immunocompetent adolescent. J Clin Microbiol 2008; 46 (09) 3169-3172
    CrossrefPubMedGoogle Scholar
  • 204 Shiva Prasad BN, Shenoy A, Nataraj KS. Primary gastrointestinal mucormycosis in an immunocompetent person. J Postgrad Med 2008; 54 (03) 211-213
    CrossrefPubMedGoogle Scholar
  • 205 Spellberg B. Gastrointestinal mucormycosis: an evolving disease. Gastroenterol Hepatol (N Y) 2012; 8 (02) 140-142
    PubMedGoogle Scholar
  • 206 O'Connor C, Farrell C, Fabre A. , et al. Near-fatal mucormycosis post-double lung transplant presenting as uncontrolled upper gastrointestinal haemorrhage. Med Mycol Case Rep 2018; 21: 30-33
    CrossrefPubMedGoogle Scholar
  • 207 Alfano G, Fontana F, Francesca D. , et al. Gastric mucormycosis in a liver and kidney transplant recipient: case report and concise review of literature. Transplant Proc 2018; 50 (03) 905-909
    CrossrefPubMedGoogle Scholar
  • 208 Kaiser P, Maggio EM, Pfammatter T. , et al. Histopathological evidence of invasive gastric mucormycosis after transarterial chemoembolization and liver transplantation. Infection 2014; 42 (04) 779-783
    CrossrefPubMedGoogle Scholar
  • 209 Nandwani A, Jha PK, Duggal R, Kher V. Invasive gastric mucormycosis and cytomegalovirus infection in an ABO incompatible renal transplant recipient. Indian J Nephrol 2015; 25 (06) 373-376
    CrossrefPubMedGoogle Scholar
  • 210 Antony SJ, Parikh MS, Ramirez R, Applebaum B, Friedman G, Do J. Gastrointestinal mucormycosis resulting in a catastrophic outcome in an immunocompetent patient. Infect Dis Rep 2015; 7 (03) 6031
    PubMedGoogle Scholar
  • 211 Knoop C, Antoine M, Vachiéry JL. , et al. Gastric perforation due to mucormycosis after heart-lung and heart transplantation. Transplantation 1998; 66 (07) 932-935
    CrossrefPubMedGoogle Scholar
  • 212 Dioverti MV, Cawcutt KA, Abidi M, Sohail MR, Walker RC, Osmon DR. Gastrointestinal mucormycosis in immunocompromised hosts. Mycoses 2015; 58 (12) 714-718
    CrossrefPubMedGoogle Scholar
  • 213 Karigane D, Kikuchi T, Sakurai M. , et al. Invasive hepatic mucormycosis: a case report and review of the literature. J Infect Chemother 2019; 25 (01) 50-53
    CrossrefPubMedGoogle Scholar
  • 214 Su H, Thompson III GR, Cohen SH. Hepatic mucormycosis with abscess formation. Diagn Microbiol Infect Dis 2012; 73 (02) 192-194
    CrossrefPubMedGoogle Scholar
  • 215 Tuysuz G, Ozdemir N, Senyuz OF. , et al. Successful management of hepatic mucormycosis in an acute lymphoblastic leukaemia patient: a case report and review of the literature. Mycoses 2014; 57 (08) 513-518
    CrossrefPubMedGoogle Scholar
  • 216 Holtom PD, Obuch AB, Ahlmann ER, Shepherd LE, Patzakis MJ. Mucormycosis of the tibia: a case report and review of the literature. Clin Orthop Relat Res 2000; (381) 222-228
    PubMedGoogle Scholar
  • 217 Katsantonis NG, Hunter JB, O'Connell BP, He J, Lewis Jr JS, Wanna GB. Temporal bone mucormycosis. Ann Otol Rhinol Laryngol 2016; 125 (10) 850-853
    CrossrefPubMedGoogle Scholar
  • 218 Koehler P, Tacke D, Cornely OA. Bone and joint infections by Mucorales, Scedosporium, Fusarium and even rarer fungi. Crit Rev Microbiol 2016; 42 (01) 158-171
    CrossrefPubMedGoogle Scholar
  • 219 Marechal E, Barry F, Dalle F. , et al. Fatal invasive otitis with skull base osteomyelitis caused by Saksenaea vasiformis . QJM 2018; 111 (07) 499-500
    CrossrefPubMedGoogle Scholar
  • 220 Taj-Aldeen SJ, Gamaletsou MN, Rammaert B. , et al; International Osteoarticular Mycoses Consortium. Bone and joint infections caused by mucormycetes: a challenging osteoarticular mycosis of the twenty-first century. Med Mycol 2017; 55 (07) 691-704
    PubMedGoogle Scholar
  • 221 Gubarev N, Separovic J, Gasparovic V, Jelic I. Successful treatment of mucormycosis endocarditis complicated by pulmonary involvement. Thorac Cardiovasc Surg 2007; 55 (04) 257-258
    Article in Thieme ConnectPubMedGoogle Scholar
  • 222 Mehta NN, Romanelli J, Sutton MG. Native aortic valve vegetative endocarditis with Cunninghamella . Eur J Echocardiogr 2004; 5 (02) 156-158
    CrossrefPubMedGoogle Scholar
  • 223 Hyvernat H, Dunais B, Burel-Vandenbos F, Guidicelli S, Bernardin G, Gari-Toussaint M. Fatal peritonitis caused by Rhizopus microsporus . Med Mycol 2010; 48 (08) 1096-1098
    CrossrefPubMedGoogle Scholar
  • 224 Rüping MJ, Heinz WJ, Kindo AJ. , et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother 2010; 65 (02) 296-302
    CrossrefPubMedGoogle Scholar
  • 225 Neofytos D, Horn D, Anaissie E. , et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48 (03) 265-273
    CrossrefPubMedGoogle Scholar
  • 226 Dannaoui E. Antifungal resistance in Mucorales. Int J Antimicrob Agents 2017; 50 (05) 617-621
    CrossrefPubMedGoogle Scholar
  • 227 Jenks JD, Salzer HJ, Prattes J, Krause R, Buchheidt D, Hoenigl M. Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy. Drug Des Devel Ther 2018; 12: 1033-1044
    CrossrefPubMedGoogle Scholar
  • 228 Tissot F, Agrawal S, Pagano L. , et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica 2017; 102 (03) 433-444
    CrossrefPubMedGoogle Scholar
  • 229 Clark NM, Grim SA, Lynch III JP. Posaconazole: use in the prophylaxis and treatment of fungal infections. Semin Respir Crit Care Med 2015; 36 (05) 767-785
    Article in Thieme ConnectPubMedGoogle Scholar
  • 230 Arikan S, Sancak B, Alp S, Hascelik G, McNicholas P. ; AHArikan S. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus . Med Mycol 2008; 46 (06) 567-573
    CrossrefPubMedGoogle Scholar
  • 231 Marty FM, Ostrosky-Zeichner L, Cornely OA. , et al; VITAL and FungiScope Mucormycosis Investigators. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis 2016; 16 (07) 828-837
    CrossrefPubMedGoogle Scholar
  • 232 Falci DR, Pasqualotto AC. Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infect Drug Resist 2013; 6: 163-174
    PubMedGoogle Scholar
  • 233 Natesan SK, Chandrasekar PH. Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations. Infect Drug Resist 2016; 9: 291-300
    CrossrefPubMedGoogle Scholar
  • 234 Guinea J, Peláez T, Recio S, Torres-Narbona M, Bouza E. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycetes, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother 2008; 52 (04) 1396-1400
    CrossrefPubMedGoogle Scholar
  • 235 Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007; 51 (07) 2587-2590
    CrossrefPubMedGoogle Scholar
  • 236 Kondori N, Svensson E, Mattsby-Baltzer I. In vitro susceptibility of filamentous fungi to itraconazole, voriconazole and posaconazole by Clinical and Laboratory Standards Institute reference method and E-test. Mycoses 2011; 54 (05) e318-e322
    CrossrefPubMedGoogle Scholar
  • 237 Pfaller MA, Messer SA, Rhomberg PR, Jones RN, Castanheira M. In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds. J Clin Microbiol 2013; 51 (08) 2608-2616
    CrossrefPubMedGoogle Scholar
  • 238 Petrikkos GL. Lipid formulations of amphotericin B as first-line treatment of zygomycosis. Clin Microbiol Infect 2009; 15 (Suppl. 05) 87-92
    PubMedGoogle Scholar
  • 239 Shoham S, Magill SS, Merz WG. , et al. Primary treatment of zygomycosis with liposomal amphotericin B: analysis of 28 cases. Med Mycol 2010; 48 (03) 511-517
    CrossrefPubMedGoogle Scholar
  • 240 van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006; 42 (07) e61-e65
    CrossrefPubMedGoogle Scholar
  • 241 Vehreschild JJ, Birtel A, Vehreschild MJ. , et al. Mucormycosis treated with posaconazole: review of 96 case reports. Crit Rev Microbiol 2013; 39 (03) 310-324
    CrossrefPubMedGoogle Scholar
  • 242 Bagshaw E, Enoch DA, Blackney M, Posthumus J, Kuessner D. Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK. Future Microbiol 2018; 13: 1283-1293
    CrossrefPubMedGoogle Scholar
  • 243 Perfect JR, Cornely OA, Heep M. , et al. Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: challenges and lessons of the VITAL trial. Mycoses 2018; 61 (07) 420-429
    CrossrefPubMedGoogle Scholar
  • 244 Denis J, Ledoux MP, Nivoix Y, Herbrecht R. Isavuconazole: a new broad-spectrum azole. Part 1: in vitro activity. J Mycol Med 2018; 28 (01) 8-14
    CrossrefPubMedGoogle Scholar
  • 245 Yoon YK, Kim MJ, Chung YG, Shin IY. Successful treatment of a case with rhino-orbital-cerebral mucormycosis by the combination of neurosurgical intervention and the sequential use of amphotericin B and posaconazole. J Korean Neurosurg Soc 2010; 47 (01) 74-77
    CrossrefPubMedGoogle Scholar
  • 246 Peel T, Daffy J, Thursky K, Stanley P, Buising K. Posaconazole as first line treatment for disseminated zygomycosis. Mycoses 2008; 51 (06) 542-545
    CrossrefPubMedGoogle Scholar
  • 247 Ervens J, Ghannoum M, Graf B, Schwartz S. Successful isavuconazole salvage therapy in a patient with invasive mucormycosis. Infection 2014; 42 (02) 429-432
    CrossrefPubMedGoogle Scholar
  • 248 Graves B, Morrissey CO, Wei A. , et al. Isavuconazole as salvage therapy for mucormycosis. Med Mycol Case Rep 2016; 11: 36-39
    CrossrefPubMedGoogle Scholar
  • 249 Garbino J, Myers C, Ambrosioni J, Gumy-Pause F. Report of a successful treatment of pulmonary Cunninghamella bertholletiae infection with liposomal amphotericin and posaconazole in a child with GvHD and review of the literature. J Pediatr Hematol Oncol 2010; 32 (02) 85-87
    CrossrefPubMedGoogle Scholar
  • 250 Epstein JB, Kupferman SB, Zabner R. , et al. Early diagnosis and successful management of oral mucormycosis in a hematopoietic stem cell transplant recipient: case report and literature review. Support Care Cancer 2016; 24 (08) 3343-3346
    CrossrefPubMedGoogle Scholar
  • 251 Ashkenazi-Hoffnung L, Bilavsky E, Avitzur Y, Amir J. Successful treatment of cutaneous zygomycosis with intravenous amphotericin B followed by oral posaconazole in a multivisceral transplant recipient. Transplantation 2010; 90 (10) 1133-1135
    CrossrefPubMedGoogle Scholar
  • 252 Peixoto D, Gagne LS, Hammond SP. , et al. Isavuconazole treatment of a patient with disseminated mucormycosis. J Clin Microbiol 2014; 52 (03) 1016-1019
    CrossrefPubMedGoogle Scholar
  • 253 Shirley M, Scott LJ. Isavuconazole: a review in invasive aspergillosis and mucormycosis. Drugs 2016; 76 (17) 1647-1657
    CrossrefPubMedGoogle Scholar
  • 254 Rausch CR, DiPippo AJ, Bose P, Kontoyiannis DP. Breakthrough fungal infections in patients with leukemia receiving isavuconazole. Clin Infect Dis 2018; 67 (10) 1610-1613
    PubMedGoogle Scholar
  • 255 Patterson TF, Thompson III GR, Denning DW. , et al. Executive summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 63 (04) 433-442
    CrossrefPubMedGoogle Scholar
  • 256 Schmitt-Hoffmann A, Desai A, Kowalski D, Pearlman H, Yamazaki T, Townsend R. Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH. Int J Clin Pharmacol Ther 2016; 54 (08) 572-580
    CrossrefPubMedGoogle Scholar
  • 257 Furfaro E, Signori A, Di Grazia C. , et al. Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy. J Antimicrob Chemother 2019; 74 (08) 2341-2346
    CrossrefPubMedGoogle Scholar
  • 258 Desai AV, Kovanda LL, Hope WW. , et al. Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi. Antimicrob Agents Chemother 2017; 61 (12) 61
    PubMedGoogle Scholar
  • 259 Tacke D, Koehler P, Markiefka B, Cornely OA. Our 2014 approach to mucormycosis. Mycoses 2014; 57 (09) 519-524
    CrossrefPubMedGoogle Scholar
  • 260 Candoni A, Aversa F, Busca A. , et al. Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data. J Chemother 2015; 27 (01) 1-12
    CrossrefPubMedGoogle Scholar
  • 261 Pagano L, Caira M, Candoni A. , et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91 (08) 1068-1075
    PubMedGoogle Scholar
  • 262 Kyvernitakis A, Torres HA, Jiang Y, Chamilos G, Lewis RE, Kontoyiannis DP. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. Clin Microbiol Infect 2016; 22 (09) 811.e1-811.e8
    CrossrefPubMedGoogle Scholar
  • 263 Mitchell TA, Hardin MO, Murray CK. , et al. Mucormycosis attributed mortality: a seven-year review of surgical and medical management. Burns 2014; 40 (08) 1689-1695
    CrossrefPubMedGoogle Scholar
  • 264 Ibrahim AS, Gebermariam T, Fu Y. , et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007; 117 (09) 2649-2657
    CrossrefPubMedGoogle Scholar
  • 265 Chitasombat MN, Niparuck P. Deferiprone as adjunctive treatment for patients with invasive mucormycosis: a retrospective case series. Infect Dis Rep 2018; 10 (02) 7765
    PubMedGoogle Scholar
  • 266 Spellberg B, Ibrahim AS, Chin-Hong PV. , et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother 2012; 67 (03) 715-722
    CrossrefPubMedGoogle Scholar
  • 267 Limper AH, Knox KS, Sarosi GA. , et al; American Thoracic Society Fungal Working Group. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med 2011; 183 (01) 96-128
    CrossrefPubMedGoogle Scholar